Sonoma Pharmaceuticals
Develops and manufactures shelf-stable hypochlorous-acid products for wound, skin, eye, foot, animal, and surface care.
Something off on this page? Send us feedback.
Profile
Sells shelf-stable hypochlorous-acid medical-device and consumer-health products for wound care, dermatology, eye care, podiatry, animal health, and surface disinfection. Revenue comes from product sales, partner distribution, custom-label development, contract manufacturing, licensing, and related technical assistance, with all production in Mexico.
Develops and manufactures shelf-stable hypochlorous-acid products under its Microcyn technology platform for wound care, dermatology, eye care, podiatry, animal health, and surface disinfection. Products span prescription, over-the-counter, office-dispense, consumer, and professional channels.
Monetizes formulations through direct professional and consumer sales, distributors, private-label and co-developed products, contract manufacturing, licensing, and some royalty or technical-assistance revenue. Human care supplies most revenue; sales extend across Europe, the United States, Asia, Latin America, and other markets.
Operates a partner-led model that combines product development, regulatory support, and manufacturing in Zapopan, Mexico. Products, manufacturing, labeling, distribution, and promotion depend on FDA and foreign-agency review, while all production is concentrated at the Mexico facility.
Company facts
Key statistics
Year to date −63.7% · Average volume (30d) 170.2K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q1 FY27 | −$0.30 | $0.02 | +106.7% | $5.0M | $6.4M | +28.4% | +10.62% |
| Jun 16, 2026Q4 FY26 | −$0.24 | −$0.09 | +62.5% | $5.6M | $5.6M | −0.1% | +4.55% |
| Feb 10, 2026Q3 FY26 | −$0.29 | −$0.35 | −20.7% | $5.5M | $4.3M | −20.6% | +1.42% |
| Nov 4, 2025Q2 FY26 | −$0.31 | −$0.13 | +58.1% | $4.3M | $5.6M | +31.5% | 0.00% |
Financial highlights
| 12 quarters | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.8M | $4.0M | $5.6M | $4.3M | $5.6M | $6.4M | |
| Gross profit | $1.5M | $1.5M | $2.1M | $1.7M | $2.2M | $2.6M | |
| Operating income | −$656.0K | −$1.1M | −$337.0K | −$678.0K | −$351.0K | −$40.0K | |
| Net income | −$776.0K | −$1.2M | −$534.0K | −$819.0K | −$581.0K | −$330.0K | |
| Diluted EPS | −$0.63 | −$0.76 | −$0.32 | −$0.48 | −$0.33 | −$0.09 | |
| Gross margin | 40.7% | 36.5% | 37.8% | 37.9% | 39.2% | 40.2% | |
| Operating margin | -17.5% | -27.3% | -6.0% | -15.6% | -6.3% | -0.6% |
Fiscal years (4-quarter sums)FY22 $12.6M · FY23 $13.3M · FY24 $12.7M · FY25 $14.3M · FY26 $19.5M
Revenue by product · Q1 FY27
Balance sheet, Jun 30, 2026Cash & short-term investments $5.3M · Total debt $739.0K · Total assets $18.1M · Shareholders' equity $6.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 1.68M · Float 1.67M · 99.4% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Geode Capital Management, LLC | 19.9K | 1.18% | 13F | May 15, 2026 |
| Vanguard Capital Management LLC | 18.8K | 1.12% | 13F | May 15, 2026 |
| DRW Securities, LLC | 12.0K | 0.71% | 13F | May 13, 2026 |
| Mckinley Carter Wealth Services, Inc. | 11.2K | 0.66% | 13F | Apr 20, 2026 |
| Morgan Stanley | 2.0K | 0.12% | 13F | May 15, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Solventum
Hospital wound-care alternative for cleansing and negative-pressure therapy.
- Smith & Nephew (ADR)
Global advanced-wound rival across dressings, infection management and NPWT.
- Organogenesis
Specialist advanced-wound rival in diabetic and chronic wound treatment.
- MiMedx
Placental-allograft rival for chronic, diabetic, and surgical wounds.
- Incyte
Prescription dermatology rival for atopic dermatitis treatment.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sonoma Pharmaceuticals | $1.31 | −0.76% | $2.2M | — | — | 0.1 | +59.6% |
| Solventum | $90.50 | −0.68% | $15.78B | 11.1 | 13.5 | 1.9 | +2.2% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Organogenesis | $1.74 | +0.29% | $223.9M | — | — | 0.5 | −56.7% |
| MiMedx | $4.50 | +0.22% | $655.9M | 112.5 | 91.3 | 1.8 | −34.7% |
| Incyte | $124.37 | −0.03% | $25.21B | 15.8 | 43.0 | 4.3 | +37.7% |
| Median | 17.5 | 43.0 | 1.9 | +2.2% |